Cargando…
Choroideremia: Update On Clinical Features And Emerging Treatments
Choroideremia (CHM) is an X-linked chorioretinal dystrophy characterized by progressive degeneration of the choroid, retinal pigment epithelium and retina. This disease is caused by mutations in the X-linked CHM gene encoding a Ras-related GTPase Rab escort protein (REP)-1, which is extremely import...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874149/ https://www.ncbi.nlm.nih.gov/pubmed/31819346 http://dx.doi.org/10.2147/OPTH.S195564 |
_version_ | 1783472785280991232 |
---|---|
author | Brambati, Maria Borrelli, Enrico Sacconi, Riccardo Bandello, Francesco Querques, Giuseppe |
author_facet | Brambati, Maria Borrelli, Enrico Sacconi, Riccardo Bandello, Francesco Querques, Giuseppe |
author_sort | Brambati, Maria |
collection | PubMed |
description | Choroideremia (CHM) is an X-linked chorioretinal dystrophy characterized by progressive degeneration of the choroid, retinal pigment epithelium and retina. This disease is caused by mutations in the X-linked CHM gene encoding a Ras-related GTPase Rab escort protein (REP)-1, which is extremely important for the retinal function. Clinically, male-affected patients have a progressive reduction in visual acuity. This disease is formally considered incurable, although new promising treatments have been recently introduced. In this article, a review of the salient pathogenetic features of choroideremia, essential for the proper interpretation of therapeutic approaches, is followed by a discussion of the fundamental clinical features of this hereditary disease. Finally, relevant new therapeutic approaches in this disease will be discussed, including gene therapy, stem cells, small molecules, and retinal prosthesis. |
format | Online Article Text |
id | pubmed-6874149 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-68741492019-12-09 Choroideremia: Update On Clinical Features And Emerging Treatments Brambati, Maria Borrelli, Enrico Sacconi, Riccardo Bandello, Francesco Querques, Giuseppe Clin Ophthalmol Review Choroideremia (CHM) is an X-linked chorioretinal dystrophy characterized by progressive degeneration of the choroid, retinal pigment epithelium and retina. This disease is caused by mutations in the X-linked CHM gene encoding a Ras-related GTPase Rab escort protein (REP)-1, which is extremely important for the retinal function. Clinically, male-affected patients have a progressive reduction in visual acuity. This disease is formally considered incurable, although new promising treatments have been recently introduced. In this article, a review of the salient pathogenetic features of choroideremia, essential for the proper interpretation of therapeutic approaches, is followed by a discussion of the fundamental clinical features of this hereditary disease. Finally, relevant new therapeutic approaches in this disease will be discussed, including gene therapy, stem cells, small molecules, and retinal prosthesis. Dove 2019-11-18 /pmc/articles/PMC6874149/ /pubmed/31819346 http://dx.doi.org/10.2147/OPTH.S195564 Text en © 2019 Brambati et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Brambati, Maria Borrelli, Enrico Sacconi, Riccardo Bandello, Francesco Querques, Giuseppe Choroideremia: Update On Clinical Features And Emerging Treatments |
title | Choroideremia: Update On Clinical Features And Emerging Treatments |
title_full | Choroideremia: Update On Clinical Features And Emerging Treatments |
title_fullStr | Choroideremia: Update On Clinical Features And Emerging Treatments |
title_full_unstemmed | Choroideremia: Update On Clinical Features And Emerging Treatments |
title_short | Choroideremia: Update On Clinical Features And Emerging Treatments |
title_sort | choroideremia: update on clinical features and emerging treatments |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874149/ https://www.ncbi.nlm.nih.gov/pubmed/31819346 http://dx.doi.org/10.2147/OPTH.S195564 |
work_keys_str_mv | AT brambatimaria choroideremiaupdateonclinicalfeaturesandemergingtreatments AT borrellienrico choroideremiaupdateonclinicalfeaturesandemergingtreatments AT sacconiriccardo choroideremiaupdateonclinicalfeaturesandemergingtreatments AT bandellofrancesco choroideremiaupdateonclinicalfeaturesandemergingtreatments AT querquesgiuseppe choroideremiaupdateonclinicalfeaturesandemergingtreatments |